Experienced in Prolymphocytic Leukemia

Dr. Mark C. Lanasa

Internal Medicine
2100 Erwin Rd, 
Durham, NC 
Experienced in Prolymphocytic Leukemia
2100 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical Research

Overview

Mark Lanasa is a primary care provider, practicing in Internal Medicine in Durham, North Carolina. Dr. Lanasa is rated as an Experienced provider by MediFind in the treatment of Prolymphocytic Leukemia. His top areas of expertise are Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), and Small Lymphocytic Lymphoma (SLL).

His clinical research consists of co-authoring 38 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Prolymphocytic Leukemia.

Specialties
Internal Medicine
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2100 Erwin Rd, Durham, NC 27710

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 05, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

38 Total Publications

Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 23, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lanasa's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile